Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neurodegenerative disease that is characterized by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibers or glial cells. [url:http://en.wikipedia.org/wiki/Synucleinopathies ]
Biomarker and diagnostic research for synucleinopathy has been reported in the published literature.
16 clinical trials registered, 9 recruiting. Interventions under study include other interventions. Pipeline includes 3 PHASE2, 1 EARLY_PHASE1, 4 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06193252](https://clinicaltrials.gov/study/NCT06193252) |
Data assembled from 3 of 12 sources · Last updated Nov 4, 2026, 12:33 AM UTC
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands
NA |
Radboud University Medical Center |
RECRUITING |
[NCT06596746](https://clinicaltrials.gov/study/NCT06596746) | Neurodegenerative Diseases Progression Markers (MARKERS-NDD) | — | Casa di Cura San Raffaele Cassino | RECRUITING |
[NCT06993142](https://clinicaltrials.gov/study/NCT06993142) | Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage | NA | Radboud University Medical Center | RECRUITING |
[NCT07187843](https://clinicaltrials.gov/study/NCT07187843) | Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD | — | Azienda USL Reggio Emilia - IRCCS | RECRUITING |
[NCT01799915](https://clinicaltrials.gov/study/NCT01799915) | Natural History Study of Synucleinopathies | — | NYU Langone Health | RECRUITING |
349 publications have been identified in PubMed for synucleinopathy. Research spans Basic Science / Preclinical (40%), Review / Meta-Analysis (22%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 121 | 40% |
Research summaries | 67 | 22% |
Testing and diagnosis research | 45 | 15% |
Disease patterns and progression | 41 | 14% |
New treatment approaches | 11 | 4% |
Clinical study results | 7 | 2% |
Other research | 4 | 1% |
Patient case studies | 3 | 1% |
Duong MT (2026). [PMID: 41603647](https://pubmed.ncbi.nlm.nih.gov/41603647/). *Mov Disord*. [Epidemiology / Natural History]
Bain A (2026). [PMID: 41522369](https://pubmed.ncbi.nlm.nih.gov/41522369/). *Alzheimers Dement (N Y)*. [Review / Meta-Analysis]
Dai W (2026). [PMID: 42001477](https://pubmed.ncbi.nlm.nih.gov/42001477/). *Expert Rev Mol Diagn*. [Review / Meta-Analysis]
Gong F (2026). [PMID: 41507136](https://pubmed.ncbi.nlm.nih.gov/41507136/). *Cell Death Dis*. [Basic Science / Preclinical]
Baranová S (2026). [PMID: 41501929](https://pubmed.ncbi.nlm.nih.gov/41501929/). *Acta Neuropathol Commun*. [Basic Science / Preclinical]
Mackie PM (2026). [PMID: 41554750](https://pubmed.ncbi.nlm.nih.gov/41554750/). *Nat Commun*. [Basic Science / Preclinical]
Gerasimenko M (2026). [PMID: 41524805](https://pubmed.ncbi.nlm.nih.gov/41524805/). *Acta Neuropathol*. [Diagnostic / Biomarker]
Palleis C (2026). [PMID: 41048081](https://pubmed.ncbi.nlm.nih.gov/41048081/). *Movement disorders : official journal of the Movement Disorder Society*. [Diagnostic / Biomarker]
Matsuse D (2026). [PMID: 41325908](https://pubmed.ncbi.nlm.nih.gov/41325908/). *Neurobiol Dis*. [Basic Science / Preclinical]
Vermorgen SMM (2026). [PMID: 41550018](https://pubmed.ncbi.nlm.nih.gov/41550018/). *Brain*. [Basic Science / Preclinical]